Cevoglitazar (0.5 mg/kg; 7 d) plasma levels of glucose and insulin were normalized.[1]
Cevoglitazar (50 and 500 mg/kg; obese and insulin-resistant cynomolgus monkeys; 4 weeks) lowered food intake and body weight in a dose-dependent manner. In these animals, cevoglitazar also reduced fasting plasma insulin and, at the highest dose, reduced hemoglobin A1c levels by 0.4%.[1]
Cevoglitazar (5 mg/kg) reduced BW gain and adiposity, independent of food intake. In the muscle, cevoglitazar improves the lipid profile via both PPARalpha- and PPARgamma-mediated mechanisms, and cevoglitazar reduced hepatic lipid concentration below baseline levels (p < 0.05). Metabolic profiling showed that in the liver, cevoglitazar functions largely through PPARalpha agonism resulting in increased beta-oxidation. Cevoglitazar only induced small changes to the lipid composition of visceral fat.[2]